- In June 2022, Avid Bioservices, Inc. opened its analytical and process development (AD/PD) suites. These suites were part of the company's lentiviral vector development and Current Good Manufacturing Plant (CGMP) manufacturing facility
- In May 2022, AGC Biologics said that it would add viral vector suspension technology and space to its commercial-grade site in Longmont, Colorado. This would make it easier to study and make gene therapies
- In September 2024, Rentschler Biopharma has introduced a new lentiviral vector manufacturing toolbox designed to enhance the production of advanced therapies. This innovative solution aims to support the growing demand for gene and cell therapies, offering improved scalability, efficiency, and safety in the manufacturing of lentiviral vectors for therapeutic applications
